All updated as on -
In 2022, this sector was estimated to be worth US$ 293.0 billion worldwide. From 2022 to 2030, it is expected to expand at a CAGR of 9.0%, reaching about US$ 624.0 Mn by 2030's end.
Cancer that starts in the bone marrow and metastasizes to other parts of the body is called acute myeloid leukaemia (AML). Rather than being a singular illness, it is a collection of diseases that affect the myeloid cell line in the bone marrow. Myeloblasts, sometimes called leukemic blasts, are the immature form of white blood cells (WBCs) responsible for AML. The accumulation of myeloblast in the bone marrow inhibits the production of healthy blood cells. This prevents the body from producing enough of its protective white blood cells, which weakens the immune system.
Because of the crucial role it plays in elucidating the cancer's genetic profile, biomarker testing plays in the diagnosis and treatment of AML. The NCCN reported that 20,050 new cases of AML will be diagnosed in the United States, with a predicted fatality rate of 11,180. More than 3,700 new cases of leukaemia are diagnosed each year in Australia. Acute leukaemia accounts for roughly 1% of all cancer diagnoses in the United States, or about 1,400 people. As a result, the high incidence of AML is expected to fuel the future expansion of the acute myeloid leukaemia (AML) biomarker testing market.
Cancer incidence and mortality rates are both greater in people aged 65 and up compared to those of younger ages. For example, the percentage of people diagnosed with cancer who are 65 and older is roughly 60%, which is ten to eleven times greater than the rate among younger people. The elderly population is expected to grow from 962 million in 2017 to 1.4 billion by the end of 2030, as reported by the World Health Organisation (WHO). By 2050, its population is expected to increase to more than 2.1 billion. As a result, the market for acute myeloid leukaemia (AML) biomarker testing solutions is expected to expand significantly over the next several years. Gene sequencing's rising popularity can be attributed to its capacity to detect mutations in more than 10 genes. The vast majority of them are thought to contribute to the process of leukemogenesis. NPM1 (27%), FLT3 (28%), IDH1 or IDH2 (20%), DNMT3A (26%), RUNX1 (10%), NRAS or KRAS (12%), TP53 (8%), TET2 (8%), WT1 (6%), and CEBPA (6%) are the most frequently mutated genes. Around 60% of cases involve mutations affecting signal activation, with FLT3 mutations being the most prevalent. According to TMR's analysis of the market, the genetics subsector will be the most lucrative in the world economy during the next few years.
From 2022 to 2031, analysts predict that North America will lead the industry. The region's established healthcare and life science sectors, as well as its early adoption of cutting-edge goods, are anticipated to fuel market growth. The rising cost of healthcare, along with rising public awareness of AML, is expected to drive up demand for AML biomarker testing in the near future. Asia-Pacific is expected to lead the world in industry growth, with a CAGR of 9.1 percent during the projection period. The region's market is expected to rise in the next years as a result of an uptick in the prevalence of AML and an increase in government investment for R&D in the detection and treatment of disease.
Recent developments in acute myeloid leukaemia (AML) biomarker testing suggest that PCR technology will continue to dominate the industry. High sensitivity and specificity, speedy diagnosis, and accurate disease progression monitoring are just a few of the many advantages of PCR. Molecular testing procedures that involve polymerase chain reaction (PCR) take advantage of amplification to produce additional copies of specific DNA or RNA. As a result, tests linked to polymerase chain reaction tend to be more sensitive. Compared to FISH techniques, those coupled with polymerase chain reaction (PCR) can probe alterations in genomic DNA with greater specificity and detail.
Report Coverage
Global Acute Myeloid Leukemia (AML) Biomarker Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Acute Myeloid Leukemia (AML) Biomarker Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Acute Myeloid Leukemia (AML) Biomarker Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Acute Myeloid Leukemia (AML) Biomarker Testing market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Acute Myeloid Leukemia (AML) Biomarker Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Acute Myeloid Leukemia (AML) Biomarker Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, Bio-Rad Laboratories, Inc., Genmark Sağlık Ürünleri, Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH (Danaher), Medaysis Company, NeoGenomics Laboratories, QIAGEN N.V., and Thermo Fisher Scientific, Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Acute Myeloid Leukemia (AML) Biomarker Testing market based on the below-mentioned segments:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By Type
Genetic
Protein
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing market, By Technology
NGS
PCR
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By End User
Research Use Only
In Vitro Diagnostic Use
Global Acute Myeloid Leukemia (AML) Biomarker Testing market, Regional Analysis
Cancer that starts in the bone marrow and metastasizes to other parts of the body is called acute myeloid leukaemia (AML). Rather than being a singular illness, it is a collection of diseases that affect the myeloid cell line in the bone marrow. Myeloblasts, sometimes called leukemic blasts, are the immature form of white blood cells (WBCs) responsible for AML. The accumulation of myeloblast in the bone marrow inhibits the production of healthy blood cells. This prevents the body from producing enough of its protective white blood cells, which weakens the immune system.
Because of the crucial role it plays in elucidating the cancer's genetic profile, biomarker testing plays in the diagnosis and treatment of AML. The NCCN reported that 20,050 new cases of AML will be diagnosed in the United States, with a predicted fatality rate of 11,180. More than 3,700 new cases of leukaemia are diagnosed each year in Australia. Acute leukaemia accounts for roughly 1% of all cancer diagnoses in the United States, or about 1,400 people. As a result, the high incidence of AML is expected to fuel the future expansion of the acute myeloid leukaemia (AML) biomarker testing market.
Cancer incidence and mortality rates are both greater in people aged 65 and up compared to those of younger ages. For example, the percentage of people diagnosed with cancer who are 65 and older is roughly 60%, which is ten to eleven times greater than the rate among younger people. The elderly population is expected to grow from 962 million in 2017 to 1.4 billion by the end of 2030, as reported by the World Health Organisation (WHO). By 2050, its population is expected to increase to more than 2.1 billion. As a result, the market for acute myeloid leukaemia (AML) biomarker testing solutions is expected to expand significantly over the next several years. Gene sequencing's rising popularity can be attributed to its capacity to detect mutations in more than 10 genes. The vast majority of them are thought to contribute to the process of leukemogenesis. NPM1 (27%), FLT3 (28%), IDH1 or IDH2 (20%), DNMT3A (26%), RUNX1 (10%), NRAS or KRAS (12%), TP53 (8%), TET2 (8%), WT1 (6%), and CEBPA (6%) are the most frequently mutated genes. Around 60% of cases involve mutations affecting signal activation, with FLT3 mutations being the most prevalent. According to TMR's analysis of the market, the genetics subsector will be the most lucrative in the world economy during the next few years.
From 2022 to 2031, analysts predict that North America will lead the industry. The region's established healthcare and life science sectors, as well as its early adoption of cutting-edge goods, are anticipated to fuel market growth. The rising cost of healthcare, along with rising public awareness of AML, is expected to drive up demand for AML biomarker testing in the near future. Asia-Pacific is expected to lead the world in industry growth, with a CAGR of 9.1 percent during the projection period. The region's market is expected to rise in the next years as a result of an uptick in the prevalence of AML and an increase in government investment for R&D in the detection and treatment of disease.
Recent developments in acute myeloid leukaemia (AML) biomarker testing suggest that PCR technology will continue to dominate the industry. High sensitivity and specificity, speedy diagnosis, and accurate disease progression monitoring are just a few of the many advantages of PCR. Molecular testing procedures that involve polymerase chain reaction (PCR) take advantage of amplification to produce additional copies of specific DNA or RNA. As a result, tests linked to polymerase chain reaction tend to be more sensitive. Compared to FISH techniques, those coupled with polymerase chain reaction (PCR) can probe alterations in genomic DNA with greater specificity and detail.
Report Coverage
Global Acute Myeloid Leukemia (AML) Biomarker Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Acute Myeloid Leukemia (AML) Biomarker Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Acute Myeloid Leukemia (AML) Biomarker Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Acute Myeloid Leukemia (AML) Biomarker Testing market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Abbott Laboratories, Bio-Rad Laboratories, Inc., Genmark Sağlık Ürünleri, Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH (Danaher), Medaysis Company, NeoGenomics Laboratories, QIAGEN N.V., and Thermo Fisher Scientific, Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Acute Myeloid Leukemia (AML) Biomarker Testing Market from 2021 to 2030.
- Market Forecast for Acute Myeloid Leukemia (AML) Biomarker Testing Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Acute Myeloid Leukemia (AML) Biomarker Testing competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Acute Myeloid Leukemia (AML) Biomarker Testing
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Acute Myeloid Leukemia (AML) Biomarker Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Acute Myeloid Leukemia (AML) Biomarker Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott Laboratories, Bio-Rad Laboratories, Inc., Genmark Sağlık Ürünleri, Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH (Danaher), Medaysis Company, NeoGenomics Laboratories, QIAGEN N.V., and Thermo Fisher Scientific, Inc.
Primary Target Market
- Market Players of Acute Myeloid Leukemia (AML) Biomarker Testing
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Acute Myeloid Leukemia (AML) Biomarker Testing market based on the below-mentioned segments:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By Type
Genetic
Protein
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing market, By Technology
NGS
PCR
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By End User
Research Use Only
In Vitro Diagnostic Use
Global Acute Myeloid Leukemia (AML) Biomarker Testing market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive acute myeloid leukemia aml biomarker testing market market research and competitor analysis for your business to help you develop more profound insights into the acute myeloid leukemia aml biomarker testing market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the acute myeloid leukemia aml biomarker testing market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.